Sodium Erythorbate / Ascorbic Acid (Cure Accelerator)

Chinese pharmaceutical company (HKEX: 1093, HQ Shijiazhuang Hebei; ~HKD 30B revenue); one of China's largest cephalosporin API and finished dose pharmaceutical manufacturers. CSPC produces 7-ACA, cephalosporin APIs (cephalexin, ceftriaxone, cefazolin), and downstream finished dose cephalosporin antibiotics for domestic and export markets. CSPC's Zhongrun Division is one of China's largest cephalosporin API producers. CSPC is headquartered in Shijiazhuang, Hebei — the same city as NCPC (North China Pharmaceutical), making Shijiazhuang the world's most concentrated antibiotic API manufacturing city. Hebei Province collectively produces a dominant fraction of global penicillin, cephalosporin, and other antibiotic APIs.

Second-largest penicillin enterprise globally and the largest Chinese producer of penicillin, amoxicillin, 6-APA, and streptomycin. Annual capacity: 7,000–8,000 tonnes antibiotics, 5,000 tonnes intermediates.

One of China's largest bulk vitamin C (ascorbic acid) fermentation producers; named defendant in the US vitamin C antitrust litigation.

Zhejiang Medicine Co., Ltd. (Hangzhou, Zhejiang, China; Shanghai Stock Exchange: 600216; ~¥8B revenue) is one of China's largest pharmaceutical and vitamin manufacturers, producing Vitamin E (all-rac-alpha-tocopherol and acetate), Vitamin A, Vitamin D3, and Vitamin C (ascorbic acid) for both human pharmaceutical and animal feed markets. Zhejiang Medicine is part of the dominant Chinese cluster of vitamin API producers that collectively supply 60-90% of global feedstock for vitamins C, D3, and several B-vitamins. Its Vitamin E production (synthetic dl-alpha-tocopherol) directly competes with BASF and dsm-firmenich in the global animal feed premix market. Zhejiang Medicine's Vitamin C (ascorbic acid) is sold under the Weishida brand and has been implicated in the 2005-2012 US court case (In re Vitamin C Antitrust Litigation) alleging that Chinese Vitamin C producers coordinated prices and quantities in violation of US antitrust law — the US Second Circuit ruled in 2021 that the coordination was not exempt from US antitrust law, reversing a lower court ruling on foreign sovereign compulsion.

dsm-firmenich AG (Kaiseraugst, Basel-Land, Switzerland; formed by merger of DSM NV Netherlands and Firmenich SA Geneva, completed May 2023; combined revenue ~€12B of which fragrance ~€3-4B) is the world's third-largest fragrance company. Firmenich (private, Geneva; founded 1895 by Philippe Chuit and Martin Naef) was the world's largest private fragrance house and the only major fragrance company to remain independent until the DSM merger. Firmenich's fragrance heritage includes Chanel No. 5 (Firmenich supplies the fragrance compound to Chanel — one of the most carefully guarded commercial relationships in the fragrance industry; the Chanel No. 5 formula is a Firmenich-originated formula from 1921). DSM contributed nutrition, health, and biosciences (vitamins, carotenoids, animal feed enzymes) to the merger. The combined dsm-firmenich operates manufacturing at Geneva (Switzerland), Haverhill (UK), Neuvy-sur-Barangeon (France), and Florham Park (USA). The Firmenich name is retained in the merged entity's fragrance operations branding.